# Influenza FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/influenza

> 4 upcoming FDA catalysts in influenza: TRX-100 (TRAW) on December 2026 (primary completion); TRX-100 (TRAW) on Dec 2026 to Mar 2027 (topline data readout); MRNA-1018-H5 (MRNA) on Jan to Apr 2027 (topline data readout); MRNA-1018-H5 (MRNA) on January 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 13, 2025 | [MRNA-1010 primary completion](https://sec-api.dev/pdufa/mrna-1010) | MRNA | Influenza | completed | "NCT05606965 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05606965)) |
| June 26, 2026 | [Participants will receive one dose of vaccine (0.5 ml) of sinovac qiv primary completion](https://sec-api.dev/pdufa/participants-will-receive-one-dose-of-vaccine) | SVA | Influenza | completed | "NCT07211152 (Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-26 (ACTUAL); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211152)) |
| November 2026 | [TRX-100 primary completion](https://sec-api.dev/pdufa/trx-100) | TRAW | Influenza | scheduled | "NCT07503405 (Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Traws Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503405)) |
| Nov 2026 to Feb 2027 | [TRX-100 topline data readout](https://sec-api.dev/pdufa/trx-100) | TRAW | Influenza | scheduled | "NCT07503405 (Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Traws Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503405)) |
| December 2026 | [TRX-100 primary completion](https://sec-api.dev/pdufa/trx-100) | TRAW | Influenza | scheduled | "NCT07371650 (This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Traws Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07371650)) |
| Dec 2026 to Mar 2027 | [TRX-100 topline data readout](https://sec-api.dev/pdufa/trx-100) | TRAW | Influenza | scheduled | "NCT07371650 (This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Traws Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07371650)) |
| Jan to Apr 2027 | [MRNA-1018-H5 topline data readout](https://sec-api.dev/pdufa/mrna-1018-h5) | MRNA | Influenza | scheduled | "NCT07496450 (A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07496450)) |
| January 2027 | [MRNA-1018-H5 primary completion](https://sec-api.dev/pdufa/mrna-1018-h5) | MRNA | Influenza | scheduled | "NCT07496450 (A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07496450)) |

## Drugs

- [MRNA-1010](https://sec-api.dev/pdufa/mrna-1010) (MRNA)
- [Participants will receive one dose of vaccine (0.5 ml) of sinovac qiv](https://sec-api.dev/pdufa/participants-will-receive-one-dose-of-vaccine) (SVA)
- [TRX-100](https://sec-api.dev/pdufa/trx-100) (TRAW)
- [MRNA-1018-H5](https://sec-api.dev/pdufa/mrna-1018-h5) (MRNA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/influenza.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Influenza FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/influenza

```bibtex
@misc{secapidev_indications_influenza_20261116,
  title        = {Influenza FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/influenza}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_influenza_20261116","title":"Influenza FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/influenza","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
